Leerink Partnrs Issues Negative Outlook for Revvity Earnings

Revvity, Inc. (NYSE:RVTY) – Equities research analysts at Leerink Partnrs lowered their Q1 2025 EPS estimates for Revvity in a report released on Friday, November 22nd. Leerink Partnrs analyst P. Souda now anticipates that the company will earn $1.09 per share for the quarter, down from their previous forecast of $1.14. The consensus estimate for Revvity’s current full-year earnings is $4.85 per share. Leerink Partnrs also issued estimates for Revvity’s Q4 2025 earnings at $1.47 EPS.

Several other research analysts have also commented on the company. JPMorgan Chase & Co. lifted their price target on Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. Raymond James upped their price target on shares of Revvity from $144.00 to $146.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Citigroup raised their price objective on shares of Revvity from $135.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. TD Cowen upped their target price on shares of Revvity from $141.00 to $144.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, Wells Fargo & Company started coverage on Revvity in a report on Tuesday, August 27th. They set an “equal weight” rating and a $130.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Revvity has an average rating of “Moderate Buy” and an average target price of $132.07.

Revvity Stock Up 0.8 %

RVTY opened at $112.03 on Monday. Revvity has a one year low of $86.30 and a one year high of $129.50. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.97 and a current ratio of 3.56. The stock has a market capitalization of $13.63 billion, a P/E ratio of 54.12, a price-to-earnings-growth ratio of 2.77 and a beta of 1.05. The business’s 50-day simple moving average is $120.53 and its 200-day simple moving average is $115.65.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.28 EPS for the quarter, topping the consensus estimate of $1.13 by $0.15. Revvity had a net margin of 9.34% and a return on equity of 7.42%. The firm had revenue of $684.10 million for the quarter, compared to analyst estimates of $679.66 million. During the same period last year, the business earned $1.18 EPS. Revvity’s revenue for the quarter was up 2.1% compared to the same quarter last year.

Institutional Investors Weigh In On Revvity

Several institutional investors and hedge funds have recently made changes to their positions in the business. EdgePoint Investment Group Inc. acquired a new position in Revvity during the second quarter worth about $209,221,000. Jane Street Group LLC increased its stake in shares of Revvity by 516.4% during the 1st quarter. Jane Street Group LLC now owns 453,343 shares of the company’s stock worth $47,601,000 after purchasing an additional 379,802 shares in the last quarter. Southpoint Capital Advisors LP acquired a new position in shares of Revvity during the 3rd quarter worth approximately $25,550,000. Janus Henderson Group PLC lifted its stake in Revvity by 1.7% in the 3rd quarter. Janus Henderson Group PLC now owns 6,335,302 shares of the company’s stock valued at $809,332,000 after buying an additional 108,401 shares in the last quarter. Finally, Holocene Advisors LP lifted its stake in Revvity by 14.6% in the 3rd quarter. Holocene Advisors LP now owns 725,917 shares of the company’s stock valued at $92,736,000 after buying an additional 92,240 shares in the last quarter. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Revvity

In other news, insider Tajinder S. Vohra sold 2,154 shares of Revvity stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total transaction of $262,206.42. Following the completion of the sale, the insider now directly owns 19,652 shares in the company, valued at approximately $2,392,237.96. This trade represents a 9.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Revvity declared that its board has authorized a share buyback program on Monday, November 4th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 6.5% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, February 7th. Shareholders of record on Friday, January 17th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, January 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.25%. Revvity’s payout ratio is currently 13.53%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.